Age, life expectancy influence termination of PSA screening

Share this article:
Age, Life Expectancy Influence Termination of PSA Screening
Age, Life Expectancy Influence Termination of PSA Screening

THURSDAY, April 26 (HealthDay News) -- Most primary care providers consider both a man's age and life expectancy in deciding whether to discontinue prostate-specific antigen (PSA) screenings, but multiple factors are involved in this decision, according to a study published online April 19 in Cancer.

Craig E. Pollack, M.D., M.H.S., from the Johns Hopkins School of Medicine in Baltimore, and colleagues surveyed 125 primary providers from a large, university-affiliated primary care practice regarding their current screening practices, factors that influence their decision to discontinue screening, and barriers to discontinuing screening.

The researchers found that 59.3 percent of the primary care providers took both age and life expectancy into account in their decisions to discontinue PSA screening, compared with 12.2 percent who did not consider either. Provider characteristics or practice styles were not associated with taking patient age and life expectancy into account. The majority (66.4 percent) of providers reported difficulty in assessing life expectancy and they differed in the age at which they typically stopped screening patients. Patient expectation and time constraints were the most frequently cited barriers to discontinuing PSA screening, cited 74.4 and 66.4 percent of the time, respectively.

"Although age and life expectancy often figured prominently in decisions to use screening, providers faced multiple barriers to discontinuing routine PSA screening," the authors write.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Challenges exist in treating HPV oropharyngeal cancer patients

Challenges exist in treating HPV oropharyngeal cancer patients

Mixed views have been expressed in relation to explaining the causal role of HPV in oropharyngeal cancer.

Views on Affordable Care Act split by political affiliation

Views on Affordable Care Act split by political ...

Health care is third most important issue to Americans in fall elections, according to polls

Poor staging linked to mortality in bladder cancer

Poor staging linked to mortality in bladder cancer

In cases of bladder cancer, omission of muscle in specimen or its mention in pathology report is linked to increased mortality.